Related Experiment Video

Updated: Nov 15, 2025

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.4K

Drug-Drug Interactions at Organic Cation Transporter 1

Shiwei Zhou1,2,3, Sujuan Zeng1, Yan Shu1,2

  • 1Key Laboratory of Oral Medicine, School and Hospital of Stomatology, Guangzhou Medical University, Guangzhou, China.

Frontiers in Pharmacology
|March 8, 2021
PubMed

Insights

Organic cation transporter 1 (OCT1) influences drug behavior. This review explores OCT1-mediated drug-drug interactions (DDIs) and their clinical importance, highlighting transporter roles in pharmacokinetics and pharmacodynamics.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Drug Metabolism

Background:

  • Drug interactions significantly impact pharmacokinetics and pharmacodynamics.
  • Organic cation transporter 1 (OCT1), part of the Solute Carrier 22A (SLC22A) family, is crucial for transporting organic cations.
  • OCT1 facilitates the movement of endogenous substances and xenobiotics across cell membranes.

Purpose of the Study:

  • To review drug-drug interactions (DDIs) mediated by OCT1.
  • To discuss the clinical significance of OCT1-mediated DDIs.

Main Methods:

  • Literature review of studies investigating OCT1.
  • Analysis of reported OCT1-mediated drug-drug interactions.
  • Evaluation of the clinical implications of these interactions.

Main Results:

  • OCT1 plays a key role in the disposition of various drugs.
  • Several drugs have been identified as OCT1 substrates, inhibitors, or inducers.
  • These interactions can lead to significant alterations in drug plasma concentrations and therapeutic outcomes.

Conclusions:

  • OCT1-mediated DDIs are clinically relevant and can affect patient treatment.
  • Understanding OCT1's role is essential for predicting and managing drug interactions.
  • Further research is needed to fully elucidate the clinical impact of OCT1 in drug therapy.
Keywords:
OCT1drug-drug interactioninhibitororganic cation transporterssubstrate

More Related Videos

Author Spotlight: Expression and Purification of Human Solute Carrier Transporters Using Codon-Optimized Genes07:10

Author Spotlight: Expression and Purification of Human Solute Carrier Transporters Using Codon-Optimized Genes

Published on: September 29, 2023

4.0K
Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting10:08

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Published on: December 9, 2022

2.4K

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
115
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
3.1K
Pore Transport and Ion-Pair Transport01:17

Pore Transport and Ion-Pair Transport

Pore transport and ion-pair formation are critical mechanisms for the absorption and distribution of drugs in the body.
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited  but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct...
888
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
758
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.2K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
457